NCT00594347

Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar

Immunogenicity and Safety of a Booster Dose of Polysaccharide Pneumococcal Vaccine (Pneumo 23®) in 12 to 18 Months-Old Children Primed With Three Doses of Pneumococcal Conjugate Vaccine (Prevnar®) in Thailand.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 339 (actual)
• Sponsor: Sanofi Pasteur, a Sanofi Company · Industry
• Sex: All
• Age: 12 Months – 18 Months
• Healthy volunteers: Accepted

Summary

The present study intends to investigate the use as a booster of a dose of sanofi pasteur's Pneumo 23 vaccine in the second year of life following 3-dose priming with Wyeth's Prevnar vaccine. The researchers will use a cohort of subjects who have received 3 doses of Prevnar® at 2, 4, 6 months of age in the context of the clinical study A3L12 on Hexavalent combined vaccine (DTaP-IPV-HB-PRP\~T)

Conditions

• Streptococcus Pneumoniae

Interventions

Type	Name	Description
BIOLOGICAL	Pneumo 23	Vaccine (Pneumo 23)
BIOLOGICAL	Prevnar	Vaccine (Prevnar)

Timeline

• Start date: 2007-11-01
• Primary completion: 2008-03-01
• Completion: 2009-04-01
• First posted: 2008-01-15
• Last updated: 2015-06-18

Locations

2 sites across 1 country: Thailand